These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 25445)

  • 21. The antiparkinsonian efficacy of bromocriptine.
    Lieberman A; Zolfaghari M; Boal D; Hassouri H; Vogel B; Battista A; Fuxe K; Goldstein M
    Neurology; 1976 May; 26(5):405-9. PubMed ID: 817221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ergot alkaloids and central monoaminergic receptors.
    Goldstein M
    J Pharmacol; 1985; 16 Suppl 3():19-24. PubMed ID: 3005775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Bromocriptine in Parkinsonian syndromes. Results obtained in a group of patients treated for 8 months].
    Quattrini A; Paggi A; Del Pesce M; Di Bella P
    Riv Patol Nerv Ment; 1978; 99(3):150-63. PubMed ID: 752907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of levodopa failures: the use of dopamine agonists.
    Lieberman AN; Gopinathan G; Neophytides A; Goldstein M
    Clin Neuropharmacol; 1986; 9 Suppl 2():S9-21. PubMed ID: 3297319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Studies on the antiparkinsonism efficacy of lergotrile.
    Lieberman A; Miyamoto T; Battista AF; Goldstein M
    Neurology; 1975 May; 25(5):459-62. PubMed ID: 166332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bromocriptine and its use in Parkinsonism.
    Hoehn MM
    J Am Geriatr Soc; 1981 Jun; 29(6):251-8. PubMed ID: 7240612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.
    Brunt ER; Brooks DJ; Korczyn AD; Montastruc JL; Stocchi F;
    J Neural Transm (Vienna); 2002 Apr; 109(4):489-502. PubMed ID: 11956968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications.
    Kuno S
    Eur Neurol; 1997; 38 Suppl 1():18-22. PubMed ID: 9276196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
    Greenamyre JT; Eller RV; Zhang Z; Ovadia A; Kurlan R; Gash DM
    Ann Neurol; 1994 Jun; 35(6):655-61. PubMed ID: 8210221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of a selective partial D1 agonist, CY 208-243, in de novo patients with Parkinson disease.
    Emre M; Rinne UK; Rascol A; Lees A; Agid Y; Lataste X
    Mov Disord; 1992; 7(3):239-43. PubMed ID: 1535688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parkinsonism from methanol poisoning: benefit from treatment with anti-Parkinson drugs.
    Davis LE; Adair JC
    Mov Disord; 1999 May; 14(3):520-2. PubMed ID: 10348484
    [No Abstract]   [Full Text] [Related]  

  • 35. [Dopamine agonists in the therapy of parkinson syndrome].
    Kapfhammer HP; Rüther E
    Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
    [No Abstract]   [Full Text] [Related]  

  • 36. Dopamine agonists as primary treatment in Parkinson's disease.
    Rinne UK
    Adv Neurol; 1987; 45():519-23. PubMed ID: 3103394
    [No Abstract]   [Full Text] [Related]  

  • 37. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined low calcium and lack magnesium is a risk factor for motor deficit in mice.
    Taniguchi R; Nakagawasai O; Tan-no K; Yamadera F; Nemoto W; Sato S; Yaoita F; Tadano T
    Biosci Biotechnol Biochem; 2013; 77(2):266-70. PubMed ID: 23391905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross tolerance between two dopaminergic ergot derivatives--bromocriptine and lergotrile.
    Teychenne PF; Rosin AJ; Plotkin CN; Calne DB
    Br J Clin Pharmacol; 1980 Jan; 9(1):47-50. PubMed ID: 6101955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.